Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04503-4
Abstract: Aim68Ga-RM2 is a bombesin (BBN) analog that targets the gastrin releasing peptide receptors (GRPR) overexpressed in many cancer cells, including prostate cancer (PC). It has been reported to successfully detect primary and recurrent PC. Here,… read more here.
Keywords: biochemically recurrent; uptake; patients biochemically; prostate cancer ... See more keywords
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of cancer"
DOI: 10.1016/j.ejca.2021.06.017
Abstract: BACKGROUND Intermittent androgen deprivation therapy (ADT) in biochemically recurrent castration-naïve prostate cancer is non-inferior to continuous therapy. We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to ADT will further reduce the duration… read more here.
Keywords: biochemically recurrent; treated group; group; prostate cancer ... See more keywords
Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study
Sign Up to like & getrecommendations! Published in 2025 at "Future Oncology"
DOI: 10.1080/14796694.2025.2479331
Abstract: ABSTRACT This podcast features two of the investigators from the international, randomized, phase 3 EMBARK trial (NCT02319837) in conversation. EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as… read more here.
Keywords: prostate cancer; embark; enzalutamide biochemically; biochemically recurrent ... See more keywords
The diagnostic performance and reader agreement of the Prostate Imaging for Recurrence Reporting system in the evaluation of local recurrence in patients with biochemically recurrent prostate cancer
Sign Up to like & getrecommendations! Published in 2025 at "Acta Radiologica"
DOI: 10.1177/02841851251334364
Abstract: Background The multiparametric magnetic resonance imaging (mpMRI)-based Prostate Imaging for Recurrence Reporting (PI-RR) system has been proposed to evaluate local recurrence in patients with prostate cancer (PCa) who have been treated with radiation therapy (RT)… read more here.
Keywords: local recurrence; prostate; pca; patients biochemically ... See more keywords
Multisite experience of fluciclovine (18F) PET/CT imaging in biochemically recurrent prostate cancer: Impact of clinical factors and intersite variation.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.6_suppl.163
Abstract: 163Background: Fluciclovine (18F) is an FDA-approved positron emission tomography/computerized tomography (PET/CT) tracer in clinical use for the detection and localization of biochemically recurrent (BCR) prostate cancer. Here, we report the impact of clinical factors and… read more here.
Keywords: prostate; biochemically recurrent; 18f pet; prostate cancer ... See more keywords
A phase II study of muscadine grape skin extract in men with biochemically recurrent prostate cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.6_suppl.248
Abstract: 248Background: Pulverized muscadine grape (Vitis rotundifolia) skin (MPX) is a potential therapeutic option for men with biochemically recurrent (BCR) prostate cancer (PCa) wishing to defer androgen deprivation therapy. MPX demonstrated antitumor effects in PCa through… read more here.
Keywords: biochemically recurrent; men biochemically; prostate cancer; muscadine grape ... See more keywords
Immunotherapy for biochemically recurrent prostate cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.215
Abstract: 215Background: Annually about 30-50,000 men are diagnosed with biochemically recurrent prostate cancer (BCRpc), defined by a rising PSA after radical prostatectomy (RP) or definitive radiation therapy (RT) with negative conventional imaging (CT and bone scan).… read more here.
Keywords: psa; recurrent prostate; biochemically recurrent; prostate cancer ... See more keywords